Who we work with
Together with our partners, we leverage knowledge, experience and insight – enabling us to deploy appropriate financial products for the market, for our partners and, ultimately, for patients.
Our partners
We start from where our partners are and work together to get where we need to be.
We work with governments, businesses, global health organisations, and civil society, to offer a new way of getting life-saving products into countries that need them.
Each of our agreements combines the expertise and resources of our partners to get medical products to the people that need them.
Discover more about who we work with to increase access to healthcare products in low- and middle-income countries.
Access to Medicines Foundation
Access to Medicines Foundation is an independent research foundation that catalyses change by triggering essential healthcare companies to play their part and raise their game on access.
BASF
Our partnership has reduced the price of 35 million next-generation Interceptor® G2 mosquito nets.
Bill & Melinda Gates Foundation
We are working together to increase access to Interceptor® G2 bed nets in malaria-endemic countries.
British International Investment
MedAccess is a wholly owned subsidiary of British International Investment (BII) and forms a key component of the UK development finance institution’s Catalyst Strategies.
Clinton Health Access Initiative
Our partnership has reduced the cost of Hologic’s Panther platform for HIV viral load testing by 40-50% in some markets.
The Foreign, Commonwealth and Development Office
MedAccess is a wholly-owned subsidiary of British International Investment (BII) which, in turn, is owned by the Foreign, Commonwealth and Development Office.
Gavi, the Vaccine Alliance
Our agreement with Gavi enables the global vaccine alliance to support continued production of antigen for the RTS,S malaria vaccine by GSK in advance of key policy and funding decisions.
The Global Fund to fight AIDS, Tuberculosis and Malaria
Our innovative finance for market-shaping helps the Global Fund to improve access to HIV, tuberculosis and malaria products.
GSK
Our partnership with Gavi and GSK supported continued production of antigen for the RTS,S malaria vaccine ahead of key policy and funding decisions.
Hologic
We are working together to increase access to viral load testing using the company’s Panther® platform. Our partnership has resulted in a $12 ceiling price per patient test.
Innovative Vector Control Consortium
IVCC is the lead implementer in the New Nets Project, funded by the Global Fund and Unitaid.
Macleods
Our volume guarantee is part of a package of measures to increase supply security and availability of Macleods’ 3HP short-course TB preventive therapy.
Open Society Foundations
We are working with the Open Society Foundations to support the COVAX cost-sharing mechanism.
PATH
We work with PATH on a volume guarantee for SD Biosensor’s G6PD testing devices and strips to help doctors administer the most effective treatment for P. vivax malaria to people with G6PD deficiency.
SD Biosensor
Our volume guarantees increase access to dual rapid testing for syphilis and HIV, and G6PD testing devices and strips to support better treatment for P. vivax malaria.
UNICEF
Our partnership is increasing and accelerating access to vital COVID-19 medical products, including diagnostic tests and clinical management supplies, in low- and middle-income countries.
Unitaid
We work with Unitaid on shaping markets for interventions against malaria and TB.
Wondfo
Our volume guarantee with Wondfo will increase access to its WHO prequalified HIV self-test.
